Discussion {#s2}
==========

Improved understanding of the molecular mechanisms and signaling pathways involved in tumor development and progression, leading to identification of potential targets (receptors and/or ligands) for anticancer therapy and development of pharmacological agents able to interfere with these targetable pathways, has resulted in therapeutic benefit in non-small cell lung cancer (NSCLC). However, SCLC has proven less amenable to a targeted approach. Few studies have attempted targeted therapy in this disease, and none has produced a strategy promising enough to progress to phase III trials \[[@B1]\].

The progress achieved in NSCLC is clearly related to the presence of powerful, predictive biomarkers (e.g., EGFR, ALK) and to access to tissue where these biomarkers are identified. The former (predictive biomarkers) and the latter (tissue obtained from biopsies) are routinely not available in SCLC.

Recently, ERK phosphorylation (pERK) has been proposed as a marker of resistance to insulin growth factor-1 receptor (IGF-1R) inhibition in SCLC \[[@B2]\]; additionally, circulating tumor cells (CTCs) have been described as a prognostic marker \[[@B3]\] and used as a source of tumor material in patients with SCLC. Furthermore, \[^18^F\]fluorodeoxyglucose-positron emission tomography \[^18^FDG-PET\] has been reported to predict response to linsitinib in mouse models of preclinical lung cancer \[[@B4]\], with "metabolic burden" similarly measured by ^18^FDG-PET scan also described as a prognostic factor in patients with SCLC \[[@B5]\]. Therefore, a reasonable personalized trial would be one in which patients with relapsed SCLC, selected by pERK expression in CTCs, are treated with linsitinib and followed with PET scans as surrogates of response and/or clinical benefit.

Unfortunately, failure of benefit with agents targeting IGF-1R, including linsitinib, has not been limited to relapsed SCLC. Indeed, the addition of monoclonal antibodies against IGF-1R, like cixutumumab (IMCA12); to platinum-doublet chemotherapy in SCLC (E1508) \[[@B6]\]; or figitumumab to chemotherapy and targeted therapies in NSCLC \[[@B7]\] also failed to provide a significant clinical benefit.

Although it is tempting to speculate that the incorporation of a predictive biomarker could have produced a different outcome in our study, the repeated failure of various IGF-1R inhibitors is difficult to ignore or to attribute to lack of reliable predictive biomarkers for patient selection. Thus, in our view, linsitinib showed no activity against relapsed SCLC and further development of this agent is not justified.

Trial Information {#s3}
=================

DiseaseLung cancer -- SCLCStage of disease / treatmentMetastatic / AdvancedPrior Therapy1 prior regimenType of study - 1Phase IIType of study - 2RandomizedProgression-Free SurvivalP: 0.1, hazard ratio (HR): 0.6Primary EndpointPFSSecondary EndpointOverall SurvivalAdditional Details of Endpoints or Study DesignStudy Design and TreatmentThis Cancer Therapy Evaluation Program (CTEP) multi-institution, randomized phase II clinical trial (ClinicalTrials.gov: NCT01533181) was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki, and applicable regulatory requirements. Approval from the institutional review board of each participating center was required, and patients provided written informed consent. Patients were randomly assigned to receive either linsitinib (150 mg orally, twice daily, every day until disease progression) or topotecan (1.5 mg/m^2^ intravenously or 2.3 mg/m^2^ orally, once daily on days 1--5 for 4 cycles). The treatment cycle was 21 days ([Fig. 1](#F1){ref-type="fig"}). Linsitinib was provided by CTEP.Safety evaluations for treatment-emergent adverse events (AEs) were performed using scheduled hematology, blood chemistry, urinalysis, vital signs, and physical examination assessments. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Two dose reductions were permitted per patient for grade 3 or 4 toxicities, with treatment resumed after AE resolution to grade 2 or below, and dose delays of up to 4 weeks were permitted to allow recovery from AEs.Primary and/or secondary prophylactic growth factor support was allowed.Tumor assessments were performed at screening and after every two cycles, using cross-sectional computed tomography and/or magnetic resonance imaging. Tumor response was evaluated by local investigator assessment and categorized according to RECIST version 1.1.Statistical AnalysisOur primary endpoint was PFS. Secondary endpoints included overall response rate, overall survival, and safety. Patients were randomly assigned 2:1 in favor of linsitinib and stratified on the basis of sensitivity to first-line treatment (sensitive vs. refractory) and performance status (0/1 vs. 2) ([Fig. 2](#F2){ref-type="fig"}).An increase in median PFS from 10 weeks (2.5 months) in the topotecan arm (control) to 16.7 weeks (4.2 months) in the linsitinib arm (experimental) was hypothesized. Using a one-sided log-rank test, an overall sample size of 95 patients (31 in the topotecan arm and 64 in the linsitinib arm) would achieve 81.6% power at an α level of 0.1 to detect a hazard ratio (HR) of 0.60 (calculation performed using PASS; NCSS Statistical Software, Kaysville, UT, <http://www.ncss.com>).Descriptive statistics were used to summarize patient characteristics and treatment administration, tumor response, and safety parameters. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method; between-treatment comparisons for OS and PFS were conducted using the log-rank test.Investigator\'s AnalysisInactive because results did not meet primary endpoint.

Drug Information Arm A topotecan {#s5}
================================

Drug 1Generic/Working nameTopotecanTrade nameHycamtinCompany nameNovartis PharmaceuticalsDrug typeChemotherapyDrug classTopoisomerase IDose1.5 mg/m^2^RouteIVSchedule of AdministrationDays 1--5

Drug Information Arm B linsitinib {#s6}
=================================

Drug 1Generic/Working nameLinsitinibTrade nameCompany nameAstellas PharmaceuticalsDrug typeSmall moleculeDrug classInsulin-like growth factors IGF-1R and IGF-2Dose150 mg per flat doseRouteOralSchedule of Administrationb.i.d.

Patient Characteristics {#s7}
=======================

Number of patients, male19Number of patients, female25StageExtensive stageAgeMedian (range): 64 (34--86)Number of prior systemic therapiesMedian (range): 1Performance Status: ECOG0 --- 36 (0--1)1 ---2 --- 83 ---Unknown ---Cancer Types or Histologic SubtypesSmall cell 44

Primary Assessment Method {#s8}
=========================

**Arm A topotecan: Small Cell**Number of patients enrolled15Number of patients evaluable for toxicity14Number of patients evaluated for efficacy15Response assessment CR*n* = 0Response assessment PR*n* = 2Response assessment SD*n* = 4Response assessment PD*n* = 9Response assessment OTHER*n* = 0(Median) duration assessments PFS3 months, CI: 1.5--3.6(Median) duration assessments OS5.3 months, CI: 2.2--7.6

**Arm B linsitinib: Small Cell**Number of patients enrolled29Number of patients evaluable for toxicity28Number of patients evaluated for efficacy29Response assessment CR*n* = 0Response assessment PR*n* = 0Response assessment SD*n* = 1Response assessment PD*n* = 28(Median) duration assessments PFS1.2 months, CI: 1.1--1.4(Median) duration assessments OS3.4 months, CI: 1.8--5.6

Assessment, Analysis, and Discussion {#s9}
====================================

CompletionStudy terminated before completionPharmacokinetics / PharmacodynamicsNot collectedInvestigator\'s AssessmentInactive because results did not meet primary endpoint
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###### Data Set
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**IRB Approved**: Yes

[Click here](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results) to access other published clinical trials.
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Patient characteristics
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###### 

Adverse events occurring in ≥2% of patients treated with linsitinib and topotecan
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